• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Female Sexual Dysfunction - Pipeline Review, H1 2012 Product Image

Female Sexual Dysfunction - Pipeline Review, H1 2012

  • ID: 2092661
  • March 2012
  • 71 pages
  • Global Markets Direct

Female Sexual Dysfunction – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Female Sexual Dysfunction - Pipeline Review, H1 2012', provides an overview of the Female Sexual Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. 'Female Sexual Dysfunction - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Female Sexual Dysfunction.
- A review of the Female Sexual Dysfunction products READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Female Sexual Dysfunction
Female Sexual Dysfunction Therapeutics under Development by Companies
Female Sexual Dysfunction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Female Sexual Dysfunction Therapeutics – Products under Development by Companies
Female Sexual Dysfunction Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Female Sexual Dysfunction Therapeutics Development
BioSante Pharmaceuticals, Inc.
Bayer AG
NexMed, Inc.
Palatin Technologies, Inc.
M et P Pharma AG
Transtech Pharma, Inc.
Medisyn Technologies, Inc.
Lipocine Inc.
Female Sexual Dysfunction – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
LibiGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-6983 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Noseafix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bremelanotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Femprox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPP515 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Goserelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Maca Root - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lactate-Containing Vaginal Lubricant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MC4R Agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaginorm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LPCN 1098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lybrido - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Female Sexual Dysfunction Therapeutics – Drug Profile Updates
Female Sexual Dysfunction Therapeutics – Discontinued Products
Female Sexual Dysfunction Therapeutics - Dormant Products
Female Sexual Dysfunction – Product Development Milestones
Featured News & Press Releases
Jan 31, 2012: BioSante Pharmaceuticals Provides Update On Clinical Development Of LibiGel
Dec 15, 2011: Apricus Bio Announces Oral Presentation Of Efficacy And Clinical Safety Data For Femprox At African Society For Sexual Medicine Conference
Dec 14, 2011: BioSante Pharmaceuticals Announces Results From LibiGel Efficacy Trials
Nov 29, 2011: Antares Pharma Announces Issuance Of New US Patent Covering LibiGel
Nov 16, 2011: BioSante Pharmaceuticals Announces Positive LibiGel Pharmacokinetic Study Results
Nov 14, 2011: Apricus Bio To Present Poster On Femprox Phase III Clinical Data At European Society of Sexual Medicine Conference
Oct 11, 2011: BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review In Phase III Program
Oct 06, 2011: Apricus Biosciences To Present Poster Of Femprox Phase III Clinical Data At Upcoming Industry Conference
Oct 04, 2011: BioSante Completes Both Pivotal LibiGel Efficacy Trials
Sep 12, 2011: BioSante Pharmaceuticals Successfully Completes LibiGel Pharmacokinetic Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Female Sexual Dysfunction, H1 2012
Products under Development for Female Sexual Dysfunction – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
BioSante Pharmaceuticals, Inc., H1 2012
Bayer AG, H1 2012
NexMed, Inc., H1 2012
Palatin Technologies, Inc., H1 2012
M et P Pharma AG, H1 2012
Transtech Pharma, Inc., H1 2012
Medisyn Technologies, Inc., H1 2012
Lipocine Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Female Sexual Dysfunction Therapeutics – Drug Profile Updates
Female Sexual Dysfunction Therapeutics – Discontinued Products
Female Sexual Dysfunction Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Female Sexual Dysfunction, H1 2012
Products under Development for Female Sexual Dysfunction – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos